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Hairy cei leukemia (HCL) is a rare chronic B-cell malignancy that, according to modern dassifi-
cations., is a subgroup of non-Hodgkin lymphomas (NHLs). A rapid increase in incidence of
NHLhas been reportedmi manycountries. The reasons forthis increase are largelyunknown, but
exposure to organochlorines has been suggted as a risk factor. Epstein-Barr virus is a human
herpesvrus that has'been associated with certain subgroups ofNHL In this study, we measured
lipid adjusted blood concentrations (in nanogr per gmm) of36 congeners ofpolychlorinated
b:iphenyls (PCBs), p,p'.-dichlorodiphenyldichloroethylene (p,p'-DDE), hexachlorobenzene
(HCB), and four subgroups ofchlorines (trans-nonachlor, cis-nonachlor, MC6, and oxychlor-
dane) inincident cases ofHCL andcontrols from thegeneralpopulation. We obtained results on
organochiorines and antibodies for 54 cases and 54 controls. Titers ofantibodies to the Epstein-
Barr early antigen and Epstein-Barr nlear antigen, measured as P107, were correlated to con-
centrations oforganochlorines to evauate the possibility ofan interaction between these factors
in the pathogenes ofHCL. We found no sficant difference in lipid-adjusted blood concen-
trations oftotal PCBs,pAp-DDE, HCB, orthe sum oftheechlordanes between cases andcontrols.
Titers ofantibodies to Epstei-Barr early antigen IgG . 40 were correlated to an increased risk
for HCL. This risk was farther increased in those with.a level above the median value ofp,p'-
DDE, HCB, or the sum ofthe chlordanessgs t a-nS interaction between Epstein-Barr virus
and a higher cooncentration ofthese chemicals. We also found increased risk for the sum of
immul;notoxic PCB group. I&y word Epstein-Barr virus, hair cell leukemia, organochlorines.
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Non-Hodgkin lymphoma (NHL) is a het-
erogeneous group of malignancies originat-
ing from the lymphoid system. There has
been a rapid increase in NHL incidence in
the Western world during the last 20-30
years (1-3).
Hairy cell leukemia (HCL) is, according
to modern classifications, a rare type of
malignant lymphoma that expresses a B-cell
phenotype (4). HCL is 4-5 times more fre-
quent in males. The possible effects on envi-
ronmental factors in the pathogenesis of
HCL have been investigated (5-11), al-
though the impact ofgenetic factors has not
been evaluated.
Many conditions characterized by severe
immunosuppression, such as immunosup-
pressive treatment after organ transplan-
tation, certain inborn immunodeficiencies,
and human immunodeficiency virus (HIV)
infection arecorrelated to an increased riskfor
NHL (12-14). Some factors suggested as
possible risk factors for NHL, such as expo-
sure to ultraviolet light and organochlorines,
have been reported to induce immunologic
changes (15,16), although the dinical impor-
tance of these findings has not been fully
evaluated (14).
Epstein-Barr virus (EBV) is a human her-
pesvirus that has a tropism for B-lymphocytes
and is found worldwide. The majority ofthe
world's adult population has antibodies to
EBV viral antigens. The primary infection
usually occurs during childhood and is often
subdinical. A latent infection is established,
which is balanced by the immune response
of the host, and antibodies to the Epstein-
Barr early antigen (EA), viral capsid antigen
(VCA), and Epstein-Barr nuclear antigen
(EBNA) maybe detected (18).
EBV has been associated with certain
types of NHL such as Burkitt lymphoma
and lymphomas occurring in immunologi-
cally compromised or HIV-infected subjects
(19). In HCL, elevated levels of antibodies
to EAandVCAhave been reported (20,21).
Polychlorinated biphenyls (PCBs) are
aromatic chemically stable compounds.
They do not occur naturally, but have been
widely used in electrical equipment and
building construction because oftheir physi-
cal properties. Theoretically, 209 congeners
ofPCBs are possible, butonlyapproximately
130 ofthese are likely to occur in commer-
cial products. Humans are exposed to PCBs
mainly through the food chain by the con-
sumption of contaminated fish, meat, and
dairy products, and PCB is stored mainly in
the adipose tissue (22). PCBs were used in
Sweden until 1973, when their use was pro-
hibited bylaw.
Exposure to PCBs has been suggested to
induce measurable changes in the immune
system (23,24), although in doses higher
than background exposure. Increased con-
centrations ofsome specific PCBs have been
shown in patients with NHL as compared to
controls (25). A recent study found a
dose-response relation between total lipid-
corrected blood concentrations oftotal PCB
(quartiles) and riskofNHLoverall (26).
DDT is an insecticide that has been
widely used because ofits chemical stability.
DDT and its metabolites p,p'-dichloro-
diphenyldichloroethylene (p,p'-DDE) and
DDD are lipid soluble and bioaccumulate.
No association has been found between
exposure to DDT and concentrations of
p,p'-DDE and NHL in samples from adi-
pose tissues in serum levels from epidemio-
logicstudies (25-27).
Hexachlorobenzene (HCB) has been used
in agriculture as a fungicide and occurs in
industry as an intermediate in chemical
processes. HCB is acontaminant in pesticides
(28). In a previous study using adipose tissue
samples, no association was found between
concentrations ofHCB andNHL (25).
Chlordanes are substances originating
from the synthesis of cyclodienes; they are
distributed throughout the biosphere.
Technical chlordane has been used both in
agriculture and in the control of termites.
Production of chlordane started in the
United States in 1947 and chlordanes were
registered in Sweden until 1969. In humans,
these compounds are stored mainly in adi-
pose tissue. Exposure to chlordane has been
suggested to induce immunologic changes
measured in lymphocyte functions in vitro
(29). An association between concentrations
ofchlordanes in adipose tissue and NHL has
been suggested (30).
According to the model of causality by
Rothman and Greenland (31), there may be
different factors acting as component causes
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in the pathogenesis of disease. To evaluate
the possibility ofmore than one factor acting
at the same time in the pathogenesis ofHCL,
concentrations oforganochlorines were cor-
related to titers of antibodies to EBV. The
purpose of this investigation was to deter-
mine concentrations of organochlorines in
blood samples from HCL patients as com-
pared to controls. The titers ofantibodies to
EBV were correlated to concentrations of
thesesubstances.
Materials and Methods
Case and control ascertainment. To investi-
gate risk factors for HCL, we performed a
population-based case-control study. The
design and other details of the study have
been published in detail elsewhere (10,11).
In short, the study included all Swedish cases
of HCL among males diagnosed between
1987 and 1992 that were reported to the
Swedish Cancer Registry and who were alive
at the time of the investigation. One case
later turned out to be diagnosed in 1993 but
was still included in the analysis. The study
included 121 cases and 484 controls drawn
from the national population registry and
matched for age, sex, and county.
The participants were sent an extensive
questionnaire with detailed questions about
previous occupations and exposure to
potential risk factors such as pesticides,
organic solvents, animals, and exhausts. The
response ratewas 91% among the cases (111
of 121) and 83% among the controls (400
of484). All data were coded blindly to the
person's case or control status. We obtained
informed consent from all participants.
Because of the high cost of analyzing
organochlorines, it was not possible to offer
blood tests to all of the participants of the
case-control study. Among these partici-
pants, 71 cases and 186 controls were ran-
domly chosen among 5-year age strata.
Sixty-two cases and ninety-four controls
agreed to participate in this part ofthe study.
Three cases and seven controls were not able
to participate because of medical reasons.
Two cases and twenty-three controls chose
not to participate although they had agreed
to give a blood sample. Blood tests were
obtained from a total of 121 individuals: 57
cases and 64 controls. One case was exclud-
ed from the analysis of antibody titers to
EBV antigens for technical reasons, and the
identity ofthe blood samples from four sub-
jects could not be identified with certainty,
so they were also excluded. Levels of
organochlorines were not obtained for three
subjects for technical reasons. Six controls
were excluded because they had a diagnosis
of a malignant disease that might interfere
with the results; organochlorines had not
been analyzed for one of these subjects
because oftechnical reasons. Results on both
viral antibodies and organochlorines were
obtained for 108 subjects: 54 cases and 54
controls. The blood samples were kept
frozen at -20°C until analysis. Results for the
sum of PCBs (36 congeners), the sum of
chlordanes (oxychlordane, MC6, and trans-
and cis-nonachlor), p,p'-DDE, HCB, and
antibody titers to EBV antigens are present-
edforthese 108 subjects.
The participants ofthis part ofthe study
were sent an additional questionnaire in
which they were asked about their present
weight and height, the weight at diagnosis of
HCL (or the year ofdiagnosis for the corre-
sponding case ofthe control), and theweight
at the time ofblood sampling. We calculated
body mass index (BMI) as theweight in kilo-
grams divided by the square ofthe height in
meters. All subjects were asked if they had
been diagnosed with a malignant disease.
The cases were further asked ifthey had been
treatedwith chemotherapyora-interferon.
EBVantigens. Antibodies to different
EBV antigens were analyzed according to
published and accredited procedures
(32,33), with the exception thatwhole blood
was used because serum or plasma were not
available. The whole EDTA-blood was
thawed, and diluted in phosphate-buffered
saline without calcium and magnesium, but
with the addition of 0.5% Tween and 5%
bovine serum albumin. In brief, we used
indirect immunofluorescence for IgG and
IgM antibodies to the VCA and the com-
bined restricted and diffuse components of
early antigens (EA R + D). The VCA IgG
antibodies were end-point titrated in 4-fold
dilutions from 1/20, whereas EA IgG was
analyzed in one dilution, allowing for the
detection of antibodies in serum dilution
. 1/40 (titer 2 1/40). Positive samples were
end-point titrated. EBNA-1 IgG antibodies
were screened in a peptide ELISA with the
alanine-glycine repeat as antigen (33). We
included well defined positive controls in
each assay. We allowed a 2-fold interassay
variation in titers of the controls in the
immunofluorescence assays. However, in the
six assays used for examination of the sam-
ples of this study there was no variation of
titers of the controls, except for one assay
where the EA control had a titer of 640
instead of320. The long-term coefficient of
variation in optical density ofthe p107 IgG
assay was < 10%; it was 3% in the six assays
for the dilution ofthe positive control with
an expected absorbance of 0.6-0.8. The
quality ofthe assays used was monitored by
participation in external quality control
schemes (External Quality Control in
Sweden), and by international serum ex-
change (mainly with E.T. Lennette, Virolab,
Inc., Berkeley, CA). The EA and VCA IgG
titers in healthy Swedes using these methods
havebeen publishedpreviously (32).
Because whole frozen EDTA blood was
the only material available for this study,
comparisons with titers found at serum or
plasma examinations were not relevant and
anticomplement studies for EBNA antibod-
ies could not be performed. The samples
were coded at the time ofexamination, and
the identity ofthe patients was unknown to
the laboratory. The completed results were
uncoded by the clinicians, and titers and
seroprevalences in cases and controls were
compared statistically.
Organochiorine analysis. We used a sub-
sample of approximately 20 mL blood plas-
ma for the analyses of 36 individual PCB
congeners, p,p'-DDE, HCB, and four chlor-
dane congeners. The plasma samples were
fortified with 13C-labeled internal PCB,
DDE, HCB, and chlordane standards. The
lipid fraction, including the organochlorines,
was retained from the plasma by use of a
Hydromatrix column (Varian, Harbor City,
CA) (34). Thereafter the lipid content was
determined gravimetrically and further
cleaned up by multilayer chromatography.
We used high resolution gas chromatography
and mass spectrometry (HRGC-MS) selected
ion monitoring (SIM) with electron impact
ionization forcongener-specific identification
and quantification of the analytes. We
achieved chromatographic separation by
splitless injection of 2 pL of the sample
(approximately 1/10) on a nonpolar DB-5
column using helium as the carrier gas. The
gas chromatography (GC) oven was pro-
grammed as follows: 180°C initial hold for 2
min, increase at a rate of 15°C/min to
205°C, followed by an increase of3.70C/min
to 3000C, and a final hold at 3000C for 20
min. In the SIM mass spectrometry (MS)
recording we monitored the two most
intense ions ofthe molecular ion dusters for
the analytes, target compounds, and stan-
dards at a dwell time of 40 msec and an
interchannel delay of 1 msec. We achieved
quantification by comparing the relative
responses of the target compounds against
the 13C internal standards in both the sam-
ples and in a standard solution. The method
detection levelwas in the range of0.3-1 ng/g
lipiddependingon the analyte's responseand
the fat content ofthe individual sample. The
recoveries of the internal standards were in
the range of 70-90% for the various
organochlorines. Laboratory blank samples
were performed in the same way as the plas-
ma samples, and theydid notcontain analyte
levels exceeding 10% of the levels found in
the samples. Further, we performed quality
assessment/quality control confirmation and
quantification when a) the signal to noise
ratio was > 3 for the quantification ions in
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the SIM GC/MS mode, b) the ratio ofthe
two most abundant ions in the chlorine clus-
ters waswithin 15% ofthe theoretical values,
and c) the HRGC retention times for the
analyte signal and the signal ofa correspond-
ingstandardwerenot more than 2 secapart.
Statistical methods. We performed
unconditional logistic regression using the
SAS system (SAS Institute, Cary, NC) for
the calculation ofodds ratios (OR) and 95%
confidence interval (CI). In the analyses,
adjustments were made for age and BMI at
the time of sampling. In addition, risk fac-
tors for HCL (11) were controlled for by
including them in the analysis (exhausts,
fungicides, herbicides, impregnating agents,
insecticides, occupational animal exposure,
and organic solvents). Antibody variables
and organochlorine variables were dichot-
omized using the median concentration of
the controls. We also used the SAS system
for descriptive statistics and Wilcoxon rank
sum tests. In one ofthe analyses we grouped
PCBs according to immunotoxic properties
(PCB nos. 66, 110, 105, 118, 74, 128/167,
156, 138, and 170/190), as previously sug-
gested (35). Because ofthe small number of
observations, formal tests of interaction
were not considered to have enough statisti-
cal power to be informative. Furthermore, a
test without the power to give significant
results does not exclude the possibility of
interaction.
Results
Results for the sum ofPCBs (36 congeners),
the sum ofchlordanes (oxychlordane, MC6,
and trans- and cis-nonachlor), p,p'-DDE,
HCB, and antibody titers to EBV antigens
are presented for 108 subjects, 54 cases, and
54 controls.
The blood samples were drawn from the
cases a median of7.1 years (range4-10 years)
after the diagnosis ofHCL and from the con-
trols a median of7.0 years (range 4-10 years)
after the diagnosis ofthe corresponding case.
The mean age at the time ofblood sampling
was 62.1 years (range 39-79) for the cases
and63.2 (range39-83) forthecontrols.
Concentrations oforganochlorines for
cases and controls are shown in Table 1. No
significant differences were found. Adivision
ofthe concentrations into tertiles to look for
a thresholdeffectdid notchange the results.
Analysis was also performed using the
median level oflipid-adjusted blood concen-
trations (in nanogram per gram) of organo-
chlorines among the controls as cut-off.
Adjusted ORs and CIs are presented in
Table 2. We found a somewhat increased
OR for the sum ofthe chlordanes; however,
it was not statistically significant. Ofthe dif-
ferent chlordanes the risk was increased for
MC6 and trans-nonachlor.
Results for analysis of the interactions
between titer to EA IgG and organochlorines
are presented in Table 3. The highest risk for
p,p'-DDE, HCB, and chlordanes was found
in the high concentration group and when
the titer to EA IgG > 40. The risk for differ-
ent chlordances was highest for MC6 and
trans-nonachlor. No clear interaction was
foundfor the sumofPCBs, although the OR
was highest in the high concentration group,
provided that the EA titerwas high. The OR
was statistically significant only in the high
PCB exposure group, butwas borderline sta-
tistically significant in the other group as
well. For the sum ofimmunotoxic PCBs the
risk was highest in the high-concentration
group (PCB > 285.4 ng/g, EA IgG > 40)
with OR = 11.3 (CI, 2.3-73.1) as compared
to in the same PCB group but with EA IgG
< 40, OR = 0.4 (CI, 0.1-0-1.5). The OR =
1.7 (CI, 0.4-7.3) in the high EA IgG titer
groupwith lowPCB (< 285.4ng/g).
Changes in body weight might influ-
ence concentrations of organochlorines.
Table 1. Levels of organochlorines calculated on
a lipid basis as nanograms per gram blood fat in
cases (n= 54) and controls (n= 54).
Organochlorinea Mean Median Range
Sum ofPCBs
Cases 847.3 811.2 382.1-1,582.7
Controls 860.2 831.6 424.0-2,138.6
p,p'-DDE
Cases 488.2 318.7 56.1-1,757.1
Controls 617.2 430.5 70.0-3,724.7
HCB
Cases 44.7 38.8 15.0-158.5
Controls 45.2 43.8 22.3-78.7
Chlordanes
Cases 48.5 40.0 14.4-267.3
Controls 50.5 44.3 16.4-198.2
Wilcoxon p-value 0.73,0.08, 0.11, and 0.42forthe sum of
PCBs,p,p-DDE, HCB, and chlordanes, respectively.
Furthermore, the concentrations increase
with age (36). Thus, adjustment was made
for BMI and age at the time ofblood sam-
pling. Westudied the changeofbodyweight
from diagnosis to the time of blood sam-
pling for cases and controls. There was a
high correlation for the weight at diagnosis
and at the time ofblood sampling for both
cases and controls; r = 0.90 and r = 0.92,
respectively. The mean increase in weight
between diagnosis and blood samplingwas 3
kg among the cases and 1.8 kg among the
controls. The mean BMI at the time of
blood sampling was 26.0 for cases and 26.6
for controls as compared to the mean BMI
at the time of diagnosis (25.1 and 26.1,
respectively). In one analysis we adjusted the
results for BMI at the time ofdiagnosis, with
similar results. Adjustment for change in
body weight in kilograms for cases and con-
trols gave similar results. Thus, in the final
statistical model adjustment was made for
age and BMI at the time ofblood sampling.
Adjusting only for BMI and weight at diag-
nosis gave similar results as when induding
other riskfactors in the model.
Table2. OR and Cl fordifferent organochlorines.
Exposed cases/
Agent(ng/g) controls OR Cl
PCB (>831.6) 23/27 0.8 0.3-1.9
Chlordanes (>44.3) 25/27 1.4 0.5-4.1
Oxychlordane (> 14) 18/26 0.8 0.3-2.2
MC6 (>4.8) 27/26 1.6 0.6-4.4
trans-Nonachlor(>22.1) 24/27 1.6 0.6-4.8
cis-Nonachlor(>2.8) 20/27 0.7 0.3-1.7
p,pJ-DDE(>430.5) 19/27 0.6 0.2-1.5
HCB (>43.8) 22/27 1.0 0.4-2.7
The median concentration (nanograms per gram fat) for
controls was used as a cut-off. The results were adjust-
edfor age and BMI atthe time ofsampling, and for expo-
sure to herbicides,fungicides, insecticides, impregnating
agents, organic solvents, animals, and exhausts.
Table 3. OR and Cl for HCLfor different exposures with the median value ofthe controls used as a cut-off
in relation totiter of EBV EA lgG.
EA<40 EA240
No. exposed No. exposed
Exposure" cases/controls OR Cl cases/controls OR Cl
Sum of PCBs
<831.6 15/23 (1.0) - 16/4 4.4 0.99-23.4
>831.6 10/21 0.4 0.1-1.4 13/6 4.4 1.2-18.5
Immunotoxic PCBsb
<285.4 14/20 (1.0) - 14/7 1.7 0.4-7.3
>285.4 11/24 0.4 0.1-1.5 15/3c 11.3 2.3-73.1
p,p'-DDE
<430.5 16/20 (1.0) - 19/7 2.8 0.8-10.7
>430.5 9/24 0.3 0.1-1.0 10/3 6.6 1.3-41.6
HCB
<43.8 14/20 (1.0) - 18/7 3.2 0.8-13.1
>43.8 11/24 0.7 0.2-2.3 11/3 10.7 2.2-68.7
Chlordanes
<44.3 11/20 (1.0) - 18/7 4.3 1.1-19.1
>44.3 14/24 1.3 0.4-5.2 11/3C 15.5 2.8-111.0
All analyses were adjusted for age and BMI at the time of sampling, and for exposure to organic solvents, herbicides,
insecticides,fungicides, impregnating agents, animals, and exhausts.
'ng/g blood fat. bPCB nos.66,110, 105, 118,74, 128/167, 156, 138, and 170/190. eSame control subjects.
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No clear pattern of association was
found regarding antibodies to P107 IgG and
concentrations of the studied organochlo-
rines (data not shown). The risk was highest
for PCBs (OR = 2.1; CI, 0.4-10.5) and
chlordanes (OR = 3.5; CI, 0.9-15.5) in the
high-exposure group, defined as concentra-
tions of these organochlorines and titer of
antibody over the median for controls. The
risk for different chlordanes was highest for
MC6 [OR = 8.2 (CI, 1.6-52.7)] and trans-
nonachlor [OR = 4.0 (CI, 0.9-18.6)],
whereas no pattern ofinteraction was found
for cis-nonachlor and oxychlordane.
The titer to the EBV (VCA IgG and
IgM) showed no difference between cases
and controls.
Discussion
One disadvantage in this study was that
blood was drawn several years after the diag-
nosis of HCL. Thus it cannot be excluded
that treatment might interfere with the
results. Most of the cases had been treated
with a-interferon or chemotherapy, most
often 2-chlorodeoxyadenosine. Only four
cases had not received any treatment at all.
Thus iswas notpossible toanalyze nontreated
patients separately. It was not possible to
resolve the issue ofa possible effect due to the
disease and/or its treatment in this case-con-
trol studybecause no baseline blood tests were
performed. In a recent study (32A, changes in
blood levels ofPCBs andp,p-DDE were seen
in women treated with chemotherapy for
breast carcinoma. However, the results were
not adjusted for possible changes in body
weightduring treatment.
The presently studied organochlorines are
fat-soluble chemicals that bioaccumulate in
the human body. The half-life in plasma for
p,p'-DDE is approximately 10 years (38) and
is approximately 10-20 years for chlordanes
(3$. No half-life time has been documented
in humans for HCB. The half-life ofPCBs is
estimated to be between 7 and 30 years (40).
Thus it is possible to estimate previous expo-
sure by measurement oflipid-based concentra-
tions of certain organochlorines. The blood
samples were drawn for all cases and controls
over a time period ofafew months and not all
at one time: This might bias the results.
However, in astudyofnonoccupational expo-
sures, chlorinated hydrocarbons were mea-
sured twice in healthywomen, an average of2
months apart. It was concluded that measure-
ments of organochlorines are stable over a
short timeperiod (41).
Because the concentrations are declining
in the Swedish population because of
restrictions in the use ofthese chemicals and
because no new high-exposure sources are
known to exist, the measured concentrations
reflect exposure some decades in the past
(42). No information exists that shows differ-
ent metabolism or elimination of these
organohalogenated hydrocarbons between
cases and controls. Thus, itwould be possible
to use ourmethod to studypast exposures.
The cases and controls in this study were
derived from a case-control study investigat-
ing possible riskfactors for HCL. Exposure to
herbicides, insecticides, fungicides, impreg-
nating agents, organic solvents, animals, and
exhaust were risk factors (11). Thus, in this
part of the study, we made adjustments for
these exposures. In one analysis, adjustment
was also made for smoking because smoking
was associated with decreased risk for HCL
(11). This did notchange the results, however
(data not shown).
We found a slightly (not significantly)
elevated OR for the presence of antibodies
to EBV early antigen IgG. Patients with
HCL have high anti-VGA and anti-EA titers
that may reflect reactivation ofa latent EBV
infection (20). An excess risk of malignant
lymphoma/leukemia has been shown in a
large Finnish cohort ofsubjects with elevated
EA and EBNA-antibody titers (43). The
main result in our investigation was the sug-
gestion ofa possible interaction between ele-
vated EA IgG and chlordanes, p,p'-DDE,
and HCB. We found no clear interaction for
PCBs, although there was an interaction in
the analysis of cases with the shortest time
between diagnosis blood sampling. This
interaction might indicate that the half-life
time and metabolism could have influenced
the results, at least for some PCBs. Further-
more, when PCBs were grouped according to
immunotoxic properties, we obtained results
similar to those from other organochlorines.
Interestingly, when analyzing the chemicals
only, without considering EBV infection, we
found no significant association, whereas in
the high titer and high-exposure group we
found significant associations. This suggests
an interaction between these chemicals and
EBV. No clear pattern was observed in the
relationship between titer to P107 IgG and
concentrations ofthese chemicals.
A recent study found a correlation
between the concentration of PCBs and the
risk for NHL in general (25). Another study
found a dose-response effect showing
increasing risk with increasing concentration
ofPCBs, and interaction with EBVwas sug-
gested (26). An increased risk for NHL has
also been suggested for high consumers of
fish from the Baltic Sea, which is contami-
nated by PCBs and other organochlorines
(44). One study ofmale capacitor-manufac-
turing workers with PCB exposure found an
increased risk for NHL (45); another study
found no increased risk (46).
Increased concentrations ofchlordanes in
adipose tissue samples from NHL patients as
compared to controls without cancer have
been reported in aSwedish study (30). This is
in agreement with our present finding. In a
case-control study on NHL, an increased risk
was found for farmers exposed to chlordanes
(47), whereas no increased risk for lymphatic
malignancies was found in a cohort ofchlor-
dane andheptachlorapplicators (48).
In a multivariate analysis ofself-reported
exposure to insecticides (11), such exposure
was not a risk factor for HCL. A pooled
analysis of three case-control studies in the
United States concluded that exposure to
DDT was not a risk factor for NHL (27);
similar results were found in previous Swedish
case-control studies on NHL (49,50).
However, the present study found an interac-
tion between concentrations ofp,p'-DDE,
the main metabolite of DDT, and titers to
EA IgG. Thus, an increased risk cannot be
excluded in subjects with seropositivity for
EBVEA.
Data of an association between HCB
and HCL are still lacking. In addition, HCB
has not been associated with NHL (25).
In conclusion, we found an increased
risk for HCL for subjects with titer to EA
IgG above the median for controls. The risk
increased further with increased concentra-
tion of certain organochlorines. Because
these organochlorines mayhave immunotox-
ic properties, an interaction between EBV
and immunotoxic chemicals may increase
the risk for HCL, as has been discussed for
NHL (14). This suggests the possibility of
EBV and organochlorines acting as compo-
nent causes in the pathogenesis of HCL.
However, the results must be interpreted
with caution because many comparisons
were made and the number ofexposed indi-
viduals was low in some ofthe calculations.
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